Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06678552 in Healthy Adults
NCT02079922Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06678552 in hypercholesterolemia (6 cohorts), sponsored by Pfizer. Primary endpoint: Assessment of adverse events, clinical laboratory tests, vital signs, and cardiac conduction intervals. Started Mar 2014; status: completed.
02
Drugs
PF-06678552
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02079922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079922.